Skip to main content
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2023 Mar 6;13:1155540. doi: 10.3389/fonc.2023.1155540

Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer

Zsuzsanna Nagy 1,2,3,*, Rinath Jeselsohn 1,2,3,4,*
PMCID: PMC10026358  PMID: 36950546

In the published article, there was an error. In the main text, some ESR1-e6>fusions that Gou and colleagues characterized were incorrectly referred to as transcriptionally inactive.

A correction has been made to “Structure and function of ESR1- e6>fusion proteins in MBC” section, Paragraph 2. This sentence previously stated:

“ESR1-e6>YAP1, ESR1-e6>SOX9, ESR1- e6>ARNT2, ESR1-e6>LPP, and ESR1-e6>NCOA1 produce active fusion proteins that are positive regulators of transcription (80, 81). In contrast to transcriptionally active ESR1-e6>fusions, multiple ESR1-e6>fusions (ESR1-e6>TCF12, ESR1-e6>ARID1B, ESR1- e6>PCDH11X, ESR1-e6>NOP2, ESR1-e6>DAB2, ESR1- e6>CLINT1, ESR1-e6>GRIP1 and ESR1-e6>TNRC6B) were identified as transcriptionally inactive despite producing stable fusion protein, adding to the complex landscape of ESR1- e6>fusion proteins.”

The corrected sentence appears below:

“The number of studies investigating the activity of ESR1-e6>fusions is limited, the function of some fusions are still unknown. Further studies are required to investigate and fully validate the stability and activity of ESR1-e6>fusions. Some ESR1-e6>fusions such as ESR1-e6>YAP1, ESR1-e6>SOX9, ESR1- e6>ARNT2, ESR1-e6>LPP, ESR1-e6>NCOA1, ESR1-e6->PCDH11X, ESR1-e6>CLINT1, ESR1-e6>GRIP1 and ESR1-e6>TNRC6B produce stable and active fusion proteins that are positive regulators of transcription (80, 81). ESR1-e6->DAB2 has cell type specific transcriptional activity- active in MCF7 but not T47D cells. In contrast to transcriptionally active ESR1-e6>fusions, multiple ESR1-e6>fusions (e.g. ESR1-e6>TCF12, ESR1-e6>ARID1B, ESR1-e6>NOP2) were identified as transcriptionally inactive despite producing stable fusion protein, adding to the complex landscape of ESR1- e6>fusion proteins.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES